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Inflammatory bowel diseases (IBD) with chronic infiltration of immune cells in the
gastrointestinal tract are common and largely incurable. The therapeutic targeting of
IBD has been hampered by the complex causality of the disease, with environmental
insults like cholesterol-enriched Western diets playing a critical role. To address this
drug development challenge, we report an easy-to-handle dietary cholesterol-based
in vivo assay that allows the screening of immune-modulatory therapeutics in transgenic
zebrafish models. An improvement in the feeding strategy with high cholesterol diet
(HCD) selectively induces a robust and consistent infiltration of myeloid cells in larvae
intestines that is highly suitable for compound discovery efforts. Using transgenics
with fluorescent reporter expression in neutrophils, we take advantage of the unique
zebrafish larvae clarity to monitor an acute inflammatory response in a whole organism
context with a fully functional innate immune system. The use of semi-automated
image acquisition and processing combined with quantitative image analysis allows
categorizing anti- or pro-inflammatory compounds based on a leukocytic inflammation
index. Our HCD gut inflammation (HCD-GI) assay is simple, cost- and time-effective as
well as highly physiological which makes it unique when compared to chemical-based
zebrafish models of IBD. Besides, diet is a highly controlled, selective and targeted
trigger of intestinal inflammation that avoids extra-intestinal outcomes and reduces the
chances of chemical-induced toxicity during screenings. We show the validity of this
assay for a screening platform by testing two dietary phenolic acids, namely gallic acid
(GA; 3,4,5-trihydroxybenzoic acid) and ferulic acid (FA; 4-hydroxy-3-methoxycinnamic
acid), with well described anti-inflammatory actions in animal models of IBD. Analysis
of common IBD therapeutics (Prednisolone and Mesalamine) proved the fidelity of our
IBD-like intestinal inflammation model. In conclusion, the HCD-GI assay can facilitate
and accelerate drug discovery efforts on IBD, by identification of novel lead molecules
with immune modulatory action on intestinal neutrophilic inflammation. This will serve
as a jumping-off point for more profound analyses of drug mechanisms and pathways
involved in early IBD immune responses.
Keywords: inflammatory bowel disease, dietary cholesterol, drug screening and discovery, innate immunity,
myeloid cells, dietary phenolic acids, inflammation and immunity
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INTRODUCTION
Inflammatory bowel diseases (IBD), like Crohn’s disease (CD),
and ulcerative colitis (UC), are chronic inflammatory disorders
of the gastrointestinal tract with significant morbidity and
mortality worldwide (Burisch et al., 2013). IBD lacks a cure
and affects circa 6.8 M people globally, bringing substantial
costs to the healthcare system and society (Burisch et al., 2013;
GBD 2017 Inflammatory Bowel Disease Collaborators et al.,
2019). Although IBD incidence is increasing, disease onset is
still unclear. The current view is that IBD arises from the
intersection of multiple factors including genetic susceptibility,
the intestinal microbiota, aberrant immune responses and
environmental insults such as diet (GBD 2017 Inflammatory
Bowel Disease Collaborators et al., 2019). This complexity makes
the development of effective therapeutic strategies for IBD highly
challenging. Coinciding with the occurrence of IBD, the rising
consumption of diets high in fat, cholesterol, protein and sugar
have been observed in the Western World (Molodecky et al.,
2012). A systematic review of 19 studies reveals an association
between Western-style diets and a higher risk of developing
IBD (Hou et al., 2011). In mice and zebrafish, acute exposure
to dietary cholesterol can induce acute innate inflammatory
responses, with interleukin-1β (IL-1β)-dependent accumulation
of myeloid cells in the intestine (Progatzky et al., 2014). This
direct pro-inflammatory effect of ingested cholesterol occurs
through inflammasome activation, involving Caspase-1 activity
in intestinal epithelial cells for the localized production of IL-1β
(Progatzky et al., 2014).
The present mainstay of IBD medical management involves
anti-inflammatory drugs (prednisolone and mesalamine),
immunomodulators (azathioprine and mercaptopurine),
antibiotics and biological agents (Damião et al., 2019). However,
none of these medications are curative, or free from having
a high number of non-responders and significant side effects
(Hossen et al., 2019). Consequently, there is an inevitable need
to develop alternative therapeutic approaches to overcome
these adverse events. As the innate immune system is known
to initiate inflammation (Holleran et al., 2017), a promising
therapeutic strategy is to target the innate immune axis at
the initial stages of IBD. In fact, classic IBD therapies like
mesalamine affect myeloid cell functions in multiple ways (Na
et al., 2019). A common bottleneck to drug discovery and
translational medicine is finding sufficiently accurate models
that reproduce central aspects of disease development and
progression. Traditional drug screening models often rely on
simple two-dimensional (2D) culture systems that are very
far from the complexity of the organs or the whole organism
(Jardine et al., 2019). Three-dimensional (3D) tissue surrogates,
like human intestinal organoids, have recently emerged as
promising strategies to develop multiplexed screening platforms
and to advance personalized medicine (Beaurivage et al., 2019).
Although these systems may recapitulate the cellular diversity
of the human intestinal epithelium, they lack immune cells
which are key contributors to normal disease development (Sato
et al., 2009; Beaurivage et al., 2019). Co-cultures of intestinal
epithelial and immune cells have been explored in trans-well
systems using transformed cell lines (Kämpfer et al., 2017); yet
those are not sufficient to bridge the translational gap to the
clinic. Recently, a 3D tissue system of the large intestine using
human biopsy-derived colonic organoids and human primary
monocyte-derived macrophages cultured in a 3D sponge scaffold
has been developed to allow epithelial-immune interactions
reflective of IBD (Roh et al., 2019). Although this system is
promising as a lead validation platform, it turns to be quite
complex for high- or even medium-throughput screening
strategies and lacks the in vivo significance.
In vivo models of IBD have proven invaluable for the
understanding of human intestinal diseases. Although, IBD
mouse models are highly instructive platforms for investigating
disease physiology, they are prohibitive for performing large-
scale in vivo compound screens. Instead, zebrafish models of
IBD provide a low-cost vertebrate model system for the initial
stages of anti-inflammatory discovery programs (Brugman et al.,
2009; Oehlers et al., 2011, 2012, 2017). Zebrafish larvae are
especially amenable due to their small size, simple manipulation
and observation, together with the fact that molecules can be
added directly into their liquid media and are rapidly absorbed
(Marjoram and Bagnat, 2015). Owing larval optical translucency
and the availability of transgenic lines with fluorescently labeled
myeloid cells (Lieschke et al., 2001; Buchan et al., 2019), zebrafish
offers the unique advantage of monitoring an acute inflammatory
response with non-invasive intravital or post-mortem imaging
(Oehlers et al., 2012, 2017). This stands to be possible as major
mammalian immune signaling mechanisms are considered to be
conserved in zebrafish (Stein et al., 2007).
Several chemical-based models of enterocolitis have
been adapted from the murine system into larval zebrafish.
Zebrafish are especially amenable to chemical induction of
gut inflammation, as larvae are simply bathed in the chemical
incitant over time, allowing it to be swallowed and to create
intestinal damage. Two high-content chemical screens on
dextran sodium sulfate- (DSS) and trinitrobenzene sulfonic
acid (TNBS)-induced zebrafish enterocolitis models have
been performed and identified novel anti-inflammatory
drugs suppressing neutrophilic inflammation (Oehlers
et al., 2017). However, in DSS and TNBS models, severe
toxicity was observed for a total of 14% of compounds
(11% for DSS; 3% for TNBS) (Oehlers et al., 2017) and both
chemicals induced extra-intestinal effects (e.g., leukocytosis)
(Oehlers et al., 2011).
To circumvent these drawbacks, we report here a diet-
targeted intestinal inflammation assay in zebrafish, that is
highly physiological, easy to work and handle, reproducible and
inexpensive. An improvement in the feeding strategy with high
cholesterol diet (HCD) selectively induces a robust and consistent
infiltration of myeloid cells in larvae intestines that is highly
suitable for drug discovery efforts. The use of semi-automated
image acquisition and processing combined with quantitative
image analysis allows quantifying intestinal neutrophilic
infiltration in transgenic zebrafish bearing fluorescently
labeled neutrophils. Besides describing the assay as well as
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its optimization, we validate its applicability in a compound
screening platform for the discovery of new immune modulatory
molecules with relevance for IBD. Likewise, this assay is suitable
for more in-depth analyses of drugs’ mechanisms of action; and
may readily provide information on off-target effects at early
phases of drug development.
MATERIALS AND EQUIPMENT
Transgenic Zebrafish
1. Tg(Lyz:NTR-mCherry)sh260 (Buchan et al., 2019), kindly
provided by Stephen Renshaw lab.
Materials
1. Polystyrene petri dishes (Thermo Scientific P5606-400EA).
2. Glass petri dishes (Fisher Scientific 11760834).
3. Eppendorf microloader pipette tips
(Eppendorf 5242 956.003).
4. Disposable graduated transfer pipettes (VWR, 414004-
036).
5. Glass pasteur pipettes 150 mm (FriLabo, 5426015N).
6. Beakers 5 mL (VWR 213-0010).
7. Disposable pestle (VWR KT749521-1500).
8. 250 mL sterile containers with lids (Corning 525-3408).
9. 1.5 mL microtubes (Abdos P10202).
10. 2 mL microtubes (Abdos P10203).
11. 12-well plates for tissue culture (VWR 10062-894).
12. 15 mL falcons (VWR 525-0604).
13. 50 mL falcons (Falcon 352070).
14. 10 mL Volumetric Pipettes (Costar Stripette 4488).
15. Pipette tips (Abdos P10102; Ahn myTip P-196816;
Sarstedt 70.1131).
16. Aluminum foil (Trato Real).
17. Glass bottom culture dishes for microscopy (VWR 734-
2906).
Reagents/Solutions
1. Embryo Medium (E3) supplemented or not with
methylene blue (see recipes).
2. Methylene blue (Sigma-Aldrich, M9140; 0.01% w/v
prepared in dH2O).
3. NaCl (Fisher Scientific S/3120/65).
4. KCl (Merck Supelco 104936).
5. CaCl2.2H2O (Sigma-Aldrich, 223506).
6. MgSO4.7H2O (Sigma-Aldrich, M1880).
7. MS-222 (25X, 4000 ppm or mg/L; see recipes).
8. Dimethyl sulfoxide (DMSO; Sigma D5879).
9. PBS 1X (see recipes).
10. Na2HPO4 (Biochem Chemopharma 319360500).
11. KH2PO4 (Fluka 60229-1KG-F).
12. Distilled water (dH2O).
13. MilliQ H2O.
14. Cholesterol (Sigma-Aldrich C8667).
15. Diethyl ether (Sigma-Aldrich 296082).
16. Standard zebrafish larval food (Sparos Lda, Zebrafeed
<100 µm; Analytical constituents: crude protein 63%,
crude fat 14%, crude ash 12%, crude fibre 1.8%).
17. Caspase 1 Inhibitor I (Sigma-Aldrich 400010).
18. Gallic acid (Sigma-Aldrich G7384).
19. Ferulic acid (Sigma-Aldrich 128708).
20. Prednisolone (Sigma-Aldrich P6004).
21. 5-Aminosalicylic acid (5-ASA or mesalamine; Sigma-
Aldrich A3537).
22. 4% w/v paraformaldehyde (PFA; Sigma, P6148) dissolved
in PBS 1X (see recipes).
23. 1% w/v low gelling temperature agarose (Sigma-Aldrich
A9414) dissolved in PBS 1X (see recipes).
Equipment
1. Digital Incubator (VWR 390-0384).
2. Stereoscopes (Leica M125).
3. Fluorescence stereoscope (Zeiss Lumar V12).
4. Motorized and automated inverted microscope
(Zeiss Axio Observer).
5. Micropipettes (Gilson).
6. Pipettor (Orange Scientific).
7. Vortex (Scientific Industries G560E).
8. Microcentrifuge (VWR, Galaxy MiniStar 0803-0298).







1. Zeiss Zen 3.0 (blue edition).
2. Huygens Software by Scientific Volume Imaging.
3. Image J 1.52c.
4. GraphPad Prism v.7.
Recipes
1. Embryo Medium (E3)
a. E3 stock (60X): Prepare 1 L by adding 17.20 g NaCl,
0.76 g KCl, 2.90 g CaCl2.2H2O and 4.90 g MgSO4.7H2O
to 800 mL distilled H2O (dH2O). Mix well. Adjust the
pH to 7.0. Add dH2O until a 1 L total volume. Autoclave
and store at 4◦C.
b. E3 (1X): Dilute 16.7 mL of E3 60X stock in dH2O
to make up 1 L. To supplement with the fungicide
methylene blue, add 3.0 mL of 0.01% w/v methylene
blue (0.01 g in 100 mL dH2O). Store at room
temperature.
2. PBS
a. PBS stock (10X): Prepare 2 L by adding 160.0 g NaCl,
4.0 g KCl, 28.8 g Na2HPO4 and 4.8 g KH2PO4 to 1.8 L
MilliQ H2O. Mix well. Adjust the pH to 7.4. Add MilliQ
H2O until a 2 L total volume.
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b. PBS (1X): Dilute 100 mL PBS 10X stock in 900 mL
MilliQ H2O. Mix well and autoclave. Store at room
temperature.
3. MS-222 (or Tricaine) solution
a. Tricaine stock (25X): Prepare 500 mL at 15 mM
(4000 ppm or mg/L) by adding 2 g MS-222 (Sigma-
Aldrich E10521) and 10 ml Tris pH 9 to 400 mL dH2O.
Adjust the pH to 7.0. Bring to 500 mL with dH2O. Store
at 4◦C.
b. Tricaine (1X): To prepare the anesthetizing solution
for the larvae, dilute the 25X stock in E3 or E3
supplemented with methylene blue to make up a
0.6 mM MS-222 (160 ppm or mg/L) final solution.
4. 4% paraformaldehyde (PFA) solution
a. Add 4 g of PFA (Sigma, P6148) to 100 mL
PBS 1X in the hood.
b. Mix with heat and shake in magnetic plate until it is
clear. Adjust the pH to 7.4. Aliquot in 2 mL tubes and
store at−20◦C.
5. 1% w/v low gelling temperature agarose
a. Add 1 g low gelling temperature agarose (Sigma, P6148)
to 100 mL PBS 1X. Heat until is clear. Aliquot in 2 mL
tubes and store at 4◦C.
b. To be ready to use, heat the aliquot at 85–90◦C and then
keep it warm at 42◦C.
METHODS
High-Cholesterol Diet Gut Inflammation
Assay – Establishment and Optimization
Animal Handling
For the high-cholesterol diet gut inflammation (HCD-GI)
assay use 6 dpf larvae arising from group matings between
heterozygous Tg(Lyz:NTR-mCherry)sh260 (Buchan et al., 2019).
Collect embryos by natural spawning and raise them in
polystyrene petri dishes at 28◦C in E3 medium supplemented
with 0.03% methylene blue as an antifungal agent. It is essential
to maintain a density of embryos not exceeding 50 per petri
dish. Great care should be taken to remove unfertilized eggs
and chorions post hatching with a plastic Pasteur pipette under
the stereoscope.
Larva Sorting
Check all larvae under a fluorescence stereoscope for
homogeneous fluorescent reporter expression, spontaneous
inflammation and appropriate age-related development. Larvae
are sorted in fresh E3 medium supplemented with 0.03%
methylene blue and MS-222 (1X; 160 mg/L). Larva sorting is
preferred at about 3 to 4 dpf. If necessary, orient larvae in a
lateral position using a flexible Eppendorf Microloader Pipette
Tip for better visualization of fluorescent reporter expression.
Place larvae in transparent 250 mL containers filled with 50 mL
E3 medium supplemented with methylene blue until 6 dpf. Close
the containers with holed lids and incubate them at 28◦C.
Preparation of Cholesterol-Enriched Diet (HCD) and
Control Diets (SP; SPE)
First weigh out 0.05 g cholesterol (Mw = 386.65 g/mol) and
0.45 g standard zebrafish larval food (SP; Sparos Lda; Zebrafeed
<100 µm) and place in a 5 mL glass beaker to create a 10% w/w
cholesterol-enriched diet, referred here as HCD. Components are
homogenized and mixed by adding 1.5 mL diethyl ether that
allows cholesterol solubilization. In another glass beaker, 1.5 mL
diethyl ether is added to 0.5 g of SP to serve as a control diet (SPE;
SP with diethyl ether). Diets are left overnight in the hood for the
diethyl ether to evaporate completely and grounded up into fine
particles using a pestle the following day.
12-Well Plate Preparation
Pre-add 3 mL of freshly made E3 medium (without methylene
blue) to each well with a 10 mL volumetric pipette. A glass Pasteur
pipette is required to handle the embryos carefully without
inflicting any wounding. Transfer single larva to each well in a
minimum E3 volume for about twelve to fifteen larvae per well.
Incubate the screening plate at 28◦C. For media changes, add
3 mL of E3 medium to each well in a new 12-well plate and
transfer larvae.
Feeding Strategy
Zebrafish larvae at 6 dpf are fed for 24 h with SPE control
diet or cholesterol-enriched diet, HCD. Feeding occurs at three
timepoints during the 24 h, with an interval of at least 6 h (see
protocol schematics in Figure 2A; see schedule below). To avoid
food deposition, media is replaced before the second feeding
time. Food is added to each well with a micropipette tip to create
a thin film at the medium surface. After the 24 h feeding period,
larvae are transferred to fresh E3 medium (3 mL) where they are
kept for 15 h without diet for intestine emptying until fixation. To
avoid the presence of any food in the wells during the 15 h period,
larvae are transferred twice to E3-filled petri dishes for wash outs
and then placed in the wells.
Recommendations:
• The food amount that is provided to larvae is the minimum
amount of powder that covers the medium surface (<1 mg).
Procedure: 1- Dip a micropipette tip into the larval food
so that the powder remains attached to the tip surface. 2 –
Beat the tip against the well wall to free the particles into
the medium surface.
• Schedule: Feeding 1: 5 pm (6 dpf) → Medium
Exchange + Feeding 2: 10 am (7 dpf) → Feeding 3:
4 pm (7 dpf) → Medium Exchange: 5 pm (no diet;
7 dpf)→ Fixation: 8 am (8 dpf).
Note:
1. For the Optimization of the HCD-GI Assay, feed 6 dpf
zebrafish larvae for 6, 12, or 24 h with HCD or control diets,
SP or SPE (see protocol schematics in Figure 3A). Feeding
occurs once for the 6 h, twice for the 12 h and three times for
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the 24 h, always with an interval of 6 h at least for multiple
feedings. After the feeding period, larvae are kept for 15 h
without diet until fixation.
Fixation
Larvae are anesthetized in E3 supplemented with tricaine
(160 mg/L; E3/T) directly in the wells and transferred in a
minimum volume to 2 mL microtubes containing 1 mL 4%
PFA solution. Incubate larvae overnight at 4◦C covered with
aluminum foil to prevent them from losing fluorescence. Rinse
them in PBS at least three times and store them in PBS at 4◦C
with aluminum foil until imaging.
Larvae Mounting and Imaging
Larvae are mounted lateral side down in 1% low gelling
temperature agarose dissolved in PBS, over glass bottom culture
dishes and overlaid with PBS for imaging. Use a flexible
Eppendorf Microloader Pipette Tip to orient larvae in a
lateral position for better visualization of fluorescent reporter
expression. Z-stack acquisition is performed with Zeiss Zen 3.0
(blue edition) software for multipositions in an automated and
motorized inverted microscope (Zeiss Axio Observer) using a
10× objective (NA 0.3) and a mercury lamp. Position the larvae
to have the more distal part of the intestine centered anterior
posteriorly and dorsal ventrally in the image. Set the lumen of
the gut as the z-center level. Image each larva in the channels
brightfield and mCherry (ex: 585 nm, em: 610 nm band pass
filters) in 49 focal planes (149 µm range; 3 µm z step) so that
all the gut depth is visible.
Image Processing and Analysis
Image deconvolution
Raw mCherry Z-stacks are deconvolved with the Huygens
Essential 20.04 (Scientific Volume Imaging, Netherlands,1), using
the classic maximum likelihood estimation (CMLE) algorithm,
with signal to noise ratio (SNR) of 40, estimated background
250, 50 iterations and a quality threshold of 0.01. The software
calculates a theoretical point spread function (PSF) to deconvolve
the images. A wide variety of parameters were first tested and the
ones used provided the best signal improvement without artifacts.
Quantification of the neutrophilic inflammation index
The quantification of the neutrophilic inflammation index (NII)
was performed using Fiji (ImageJ) after image deconvolution
(see image processing and analysis pipeline in Supplementary
Figure 1; see example in Figures 2B,C). Maximum intensity
projection (MIP) images from 49 focal planes are generated
for each of the channels. Guts are manually drawn using the
brightfield MIP image to create a gut region-of-interest (ROI).
Care is taken to exclude pigments from the gut ROI. The
mCherry MIP image is manually thresholded to create a mask
for the red fluorescent leukocytes, reflected as red pixels in the
image. Finally, the area fraction of the red pixels in the gut ROI is
obtained with the Measurement > Area Fraction tool to calculate
the percent area occupied by neutrophils in the defined area of
the intestine, i.e., the NII.
1http://svi.nl
Statistical analysis
Statistical analysis was performed in GraphPad Prism v7 and
statistical significance was considered for p < 0.05. Comparison
between samples was performed by a nonparametric Mann–
Whitney test.
Potential Applications
The new HCD-GI assay is highly physiological and suitable for
translational, cellular or molecular applications, specifically:
(i) To develop a drug-discovery platform with relevance
for IBD. This assay can be exploited to test molecules for
their effect on the initiation step of intestinal neutrophilic
inflammation in the context of drug-repurposing or new
compound screens;
(ii) To identify dosage, tolerance, toxicity or off-target effects of
leads at early stages of drug development;
(iii) For in-depth analyses of drug signaling mechanisms involved
in the orchestration of innate immune responses in IBD.
The signaling pathways underlying HCD-induced
intestinal innate inflammation are well characterized in
zebrafish (Progatzky et al., 2014). These are a solid base
for successive investigation of leads’ activity at a molecular
level;
(iv) To identify mutations affecting leukocyte migration during
intestinal inflammation.
HCD-GI Discovery Platform
We have developed a drug-discovery platform with relevance
for IBD (i) – the HCD-GI discovery platform (see schematics
in Figure 1 and Figure 4A) -, which can be used to test any
soluble drug, signaling inhibitor, natural compound or small
molecule. For a first-pass screening strategy, we suggest exposing
the larvae to the compounds at two different concentrations
(25 and 100 µM) throughout the whole assay. This is a good
treatment option that increases the chance of identifying as many
compounds as possible targeting an intestinal inflammation
process at its initiation step. Based on the NII, the effects of
the compounds can be evaluated at the end of the assay and
categorized as anti- or pro-inflammatory. Importantly, Caspase 1
Inhibitor is used as an effective anti-inflammatory drug control of
the screening platform whose molecular action is well-described
(Progatzky et al., 2014). This inhibitor blocks IL-1β production
in intestinal epithelial cells after HCD-exposure, a cytokine
important for intestinal myeloid cells’ infiltration in this model
(Progatzky et al., 2014).
Preclinical proof-of-concept of the platform is exemplified by
testing the effects of gallic acid (GA) and ferulic acid (FA) on
HCD-driven intestinal inflammation phenotype. GA and FA are
active compounds found in many fruits and plants and exhibit
anti-inflammatory protective effects in mouse models of IBD
(Sadar et al., 2007; Pandurangan et al., 2015; Kandhare et al., 2016;
Hossen et al., 2019; Zhu et al., 2019; Yang et al., 2020). After a first
pass screening strategy, GA and FA are validated in dose-response
experiments to find their IC50 and the lowest concentrations
at which they are active. Notably, the clinical fidelity of our
IBD-like platform is ultimately demonstrated by monitoring the
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FIGURE 1 | The high-cholesterol diet gut inflammation (HCD-GI) discovery platform. Schematic diagram illustrating the screening strategy for compounds
modulating inflammation. Individual Tg(Lyz:NTR-mCherry)sh260 larvae, with fluorescent reporter expression in neutrophils, are distributed in 12-well plates with E3
zebrafish (ZF) medium supplemented with the compounds at 25 or 100 µM. After 1 h pre-treatment, larvae are fed with high-cholesterol diet (HCD) for 24 h. Larvae
are then transferred to fresh medium supplemented with compounds were are kept for 15 h to allow inflammation and proper intestine emptying to occur. Larvae are
finally fixed and imaged. Screening data are processed, and the neutrophilic inflammation index analyzed. Figure performed with images from Biorender.
effects of common IBD therapeutics, namely mesalamine and
prednisolone (Oehlers et al., 2011, 2017), in NII values.
Animal Handling, Larva Sorting, Preparation of Diets,
Fixation, Imaging and Image Processing and Analysis are
performed as described in HCD-GI Assay – Establishment
and Optimization.
Preparation of Compounds
First weigh out all the compounds under test (here exemplified
for GA and FA) and the screening control (Caspase 1 Inhibitor
I). Prepare 10 mM stock solutions in DMSO. Make aliquots to
eliminate the need to expose compounds to repeated freeze/thaw
cycling. Make DMSO aliquots for the negative and diet controls.
Protect them from light and store at−20◦C.
12-Well Plate Preparation With the Compounds
Pre-add 2.970 or 2.992 mL of freshly made E3 medium to each
well, in accordance with the volume of compound that will
be added. Mix compounds in the stock aliquot three times by
pipetting up and down or by vortexing. Add 30 µl (for 100 µM
solution) or 7.5 µl (for 25 µM solution) compound stock to each
well and mix medium in wells four times to ensure homogenous
distribution of the compound within the well. Transfer single
larva with a glass pipette to each well in a minimum E3 volume
for about twelve to fifteen larvae per well. Incubate the screening
plate at 28◦C covered with aluminum foil to protect compounds
from light. For media changes, use the same procedure.
Recommendation:
• Keep minimal the amount of medium that is added to the
wells during larvae transfer to avoid diluting the screening
solutions. Use glass Pasteur pipettes with a very small hole
and let larvae accumulate in groups at their tips and swim
directly to the medium.
Screening Controls
Treatment with 30 µl DMSO (or 1% DMSO; vehicle) in SPE-
fed larvae is used as diet control. 1% DMSO in HCD-fed
animals works as negative control. Caspase 1 Inhibitor I (30 µl;
100 µM solution) in HCD-fed animals is used as positive anti-
inflammatory control (Progatzky et al., 2014).
Feeding and Treatment Strategies
Zebrafish larvae at 6 dpf are fed for 24 h with HCD in the presence
of 25 or 100 µM compounds. Feeding occurs at three timepoints
during the 24 h, with an interval of at least 6 h (see protocol
schematics in Figure 1 and Figure 4A; see schedule below).
The first feeding event occurs 1 h after larvae pretreatment
with the compounds. To avoid food deposition and compound
degradation, E3 media with 25 or 100 µM compounds is replaced
before the second feeding time. After the 24 h feeding period,
larvae are transferred to fresh E3 medium supplemented with the
compounds at 25 or 100 µM where they are kept for 15 h without
diet until fixation. To avoid the presence of any food in the wells
during the 15 h period, larvae are transferred twice to E3-filled
petri dishes for wash outs and then placed in the wells.
Recommendations:
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• The food amount that is provided to larvae is the minimum
amount of powder that covers the medium surface (<1 mg)
(see HCD-GI Assay – Feeding strategy).
• After adding the food, let the larvae at room temperature
with little light for 1 h. This ensures feeding to
occur and avoids degradation of compounds with
light. Then, incubate the screening plate at 28◦C
covered with aluminum foil until the next feeding or
medium exchange event.
• Schedule: Treatment 1: 4 pm (6 dpf) → Feeding 1: 5 pm
(6 dpf) → Medium exchange/Treatment 2 + Feeding 2:
10 am (7 dpf) → Feeding 3: 4 pm (7 dpf) → Medium
exchange/Treatment 3: 5 pm (no diet; 7 dpf)→ Fixation:
8 am (8 dpf).
Dose-Response Experiments and Clinical Validation
For dose-response experiments or clinical validation adapt the
volumes of E3 and compounds appositely in 12-well plate
preparation with the compounds and in HCD-GI discovery
platform. All stock solutions are prepared in DMSO at 10 mM
concentration, apart from mesalamine, for which a 131 mM stock
solution is prepared.
Statistical Analysis
Statistical analysis was performed in GraphPad Prism v7 and
statistical significance was considered for p < 0.05. Non-
parametric Kruskal–Wallis test (one-way ANOVA on ranks) was
used for multiple comparisons. The half maximal inhibitory
concentration (IC50) was calculated based on a nonlinear
regression using a four-parameter variable slope.
(EXAMPLE) RESULTS
The HCD-GI Assay
The HCD-GI assay is a simple, reproducible, economic and
physiological model of innate intestinal inflammation with
powerful applicability for a compound discovery platform in
the whole organism system (Figure 1). Neutrophilic distribution
is a generally used live readout of inflammation in larval
zebrafish enterocolitis models (Oehlers et al., 2017). Under
physiological conditions, neutrophils are primarily located in
the caudal hematopoietic tissue (CHT) in the zebrafish larvae
(Guyader et al., 2008). Exposure to chemical or environmental
gut incitants causes a qualitative shift in neutrophil localization
to the intestine (Oehlers et al., 2011; Progatzky et al., 2014).
Examination of this phenotype for medium or high-throughput
and high-content (HT/HC) efforts allows the identification of
compounds exacerbating inflammation (pro-inflammatory) or
inhibiting it (anti-inflammatory). Here we use dietary cholesterol
as a highly physiological trigger of intestinal inflammation in
zebrafish larvae (Progatzky et al., 2014). In contrast to chemically
induced zebrafish enterocolitis models, dietary cholesterol targets
inflammation selectively to the intestine when added acutely
(Progatzky et al., 2014) and the chances of compound-induced
toxicity are low.
Prior reports have revealed that zebrafish larvae fed for 6 h
with dietary cholesterol develop acute innate inflammation with
myeloid cell infiltration in the intestines (Progatzky et al., 2014).
Significant differences in myeloid cell accumulation were only
found using doses of 4% cholesterol with groups of about 30
larvae, and power calculations determined significant differences
for 2% cholesterol when using n = 190 (Progatzky et al., 2014).
Since these numbers are too high for a screening platform, we
here develop an improved feeding strategy with more robust and
adequate immune responses for this type of application.
In the HCD-GI assay, 6 dpf larvae are fed ad libitum three
times during a 24 h period with 10% w/w cholesterol-enriched
diet (HCD) or control larval diet (SPE; prepared as HCD
but without cholesterol addition; see recipes) (Figure 2A). The
assay is performed in Tg(Lyz:NTR-mCherry)sh260 larvae, where
neutrophils are marked by the expression of monomeric Cherry
(mCherry) (Buchan et al., 2019) (Figure 2A). We monitor the
presence of mCherry+ neutrophils in larval intestines 15 h post
feeding (Figure 2B). We choose this timepoint of observation
for two main reasons: (1) To ensure perfect intestine emptying
after feeding; (2) A peak of inflammation has been proposed
to occur 15 to 18 h post HCD feeding and to resolve at about
24 h (Progatzky et al., 2014). Brightfield and mCherry images
are collected and the quantification of NII is performed using
Fiji (ImageJ) after image deconvolution. Briefly, the gut area is
manually drawn. Then, a threshold is applied to the mCherry
image to reduce the operator bias (Image – Adjust – Threshold).
Finally, the area fraction of the mCherry pixels in the intestine
is obtained with the Measure tool (Set Measurements > Area
Fraction), and this value corresponds to the NII (Figure 2C
and Supplementary Figure 1). Taking into account the intrinsic
variability in food intake by larvae during feeding we show the
robustness of our protocol using a sample size n of about 12
larvae. We observe a strong inflammatory response in HCD-fed
animals compared to SPE controls using groups of only 10 to 12
larvae (Figure 2D). These numbers are perfectly compatible with
screening strategies.
Protocol Optimization
For prior protocol optimization, a range of feeding times – 6,
12, and 24 h – were tested to establish the time that causes
the strongest and most consistent inflammation with HCD
(Figure 3A). 6 dpf larvae were fed ad libitum for 6 to 24 h with
HCD or control larval diets. As control larval diets we tested
standard zebrafish larval food (SP) or SP supplemented with
diethyl ether (SPE), the organic solvent that helps solubilizing
cholesterol in the cholesterol-enriched diet, HCD. At first, we
looked whether the diethyl ether could non-specifically induce
an inflammation phenotype. To this aim, we compared the
inflammation index NII in SPE and SP groups aggregating the
data from all feeding times. No significant differences were
detected between these control groups (Figure 3B). This suggests
that the phenotype observed in HCD-fed animals is highly
specific to cholesterol enrichment and discards any effect of the
organic solvent in the observed inflammation phenotype. Since
the diethyl ether is left to evaporate overnight from the diet this
result is expected. Thus, we use SPE as the proper control diet
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FIGURE 2 | The HCD-gut inflammation (HCD-GI) assay. (A) Schematic representation of the protocol optimized for the HCD-GI assay in 6 dpf
Tg(Lyz:NTR-mCherry)sh260 (Progatzky et al., 2014). (B) Representative images of distal intestine at 15 h following SPE or HCD feeding for a 24 h period. White
arrows correspond to mCherry+ neutrophils in the intestines. Yellow arrows correspond to autofluorescence caused by pigments. (C) Image processing used for the
quantification of neutrophilic inflammation index (NII) in larvae from (B). NII values for the representative SPE or HCD larvae are shown in red. (D) NII quantification.
One representative experiment of n = 12 larvae is shown. Each dot represents one larva. Two-tailed Mann Whitney test. **P < 0.01. Error bars represent SEM. Scale
bars = 100 µm. Scheme (A) performed with images from Biorender.
in the HCD-GI assay. Secondly, by comparing HCD-fed animals
with SPE controls for the different feeding times, significant
differences in the inflammation index occur after 12 or 24 h
feeding using groups of 10 to 12 larvae (Figure 3C). Still, we favor
the 24 h versus the 12 h feeding strategy for the HCD-GI assay
because: (1) The strength of inflammation in HCD-fed animals
relative to SPE controls is comparably higher (Figures 3B,C); (2)
The increase of inflammation observed in HCD-treated animals
respect to SPE controls is more consistent and reproducible
(Figure 3D); (3) The success of individual experiments is a
mandatory factor for a reliable discovery platform (Figure 3D).
Applications: The HCD-GI Discovery
Platform
To demonstrate the potential of our model for screening
strategies, we developed the HCD-GI discovery platform
(Figure 4A). In our platform, the HCD-GI assay is performed
in the presence of the compounds throughout all the procedure.
We opt for a prolonged compound treatment to increase the
chances of identifying molecules with putative actions at the
onset of intestinal inflammation. We also choose to employ the
compounds at two different concentrations to avoid an erratic
exclusion of compounds with no activity at the lowest one.
With this strategy we can also find an initial range of action for
each compound, to use in successive dose-response experiments.
Therefore, we test a concentration commonly used in zebrafish
drug screens - 25 µM (Rennekamp and Peterson, 2015) -, and
also a higher concentration – 100 µM -, that turns to be useful
when testing natural compounds with low toxicity and, possibly,
lower activity (Figure 4A).
For the HCD-GI discovery platform, we use a sample size n
of 12 to 15 larvae, and we prepare duplicates of control samples
to provide robustness to the data. Since all compound stocks
are dissolved in DMSO, we first determined if the concentration
of the vehicle could non-specifically generate an inflammatory
phenotype. In a dose-response analysis ranging from 0.01–
1% DMSO, concentrations up to 1% have no effect in the
neutrophilic inflammation index, NII (Figure 4B). Being 1%
DMSO the highest concentration present in the liquid media
of the animals under test (when exposed to compounds at
100 µM), we use it as a vehicle control in HCD- and SPE-fed
larvae (see samples below). On the other hand, we use Caspase-1
inhibitor as the anti-inflammatory drug control of the platform,
whose molecular action blocking HCD responses is well-known
(Progatzky et al., 2014).
In summary, samples in the platform are:
(i) Control diet: SPE+ 1% DMSO.
(ii) Negative control: HCD+ 1% DMSO.
(iii) Anti-inflammatory drug control: HCD + Caspase 1
Inhibitor I (100 µM final concentration).
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FIGURE 3 | Protocol optimization for the HCD-GI assay. (A) Schematic representation of the optimization protocol used to establish the HCD-GI assay in 6 dpf
Tg(Lyz:NTR-mCherry)sh260. (B) Box plots of mean neutrophilic inflammation index (NII) quantification at 15 h following feeding with standard zebrafish larval food
(SP) or SP supplemented with the cholesterol solubilizer diethyl ether (SPE). Data were aggregated from one representative experiment of n = 10–12 larvae fed for 6,
12, or 24 h. Total number of averaged larvae is disclosed in parenthesis. Central lines represent median values, whereas box edges represent the 25 and 75th
percentiles. (C) Neutrophilic inflammation index (NII) quantification at 15 h following HCD or control diet SPE feeding for a 6- (Progatzky et al., 2014), 12-, or 24 h
period. One representative experiment of n = 10–12 larvae is shown. Each dot represents one larva. Error bars represent SEM. (D) Arrow plots of mean NII values.
Mean NII of pools of n = 10–12 larvae were calculated for 4–5 independent experiments and represented by dots. SPE – Black dots; HCD – Red dots. The gray
dashed arrows indicate the difference between mean NII in SPE- and HCD-fed animals in individual experiments. Two-tailed Mann Whitney test. **P < 0.01; n,
non-significant. Scheme (A) performed with images from Biorender.
(iv) n compounds under test: HCD + n compounds (25- or
100 µM final concentration).
As a proof-of-concept for the HCD-GI discovery platform,
we test two natural compounds, namely gallic acid (GA) and
ferulic acid (FA), with known antioxidant and anti-inflammatory
actions in mouse models of IBD (Figure 4C; Chaudhary et al.,
2019; Kahkeshani et al., 2019). As expected, HCD-fed larvae
show a strong inflammatory response with respect to the SPE
counterpart. This inflammatory response is efficiently reduced
to basal levels in the presence of Caspase-1 inhibitor, the anti-
inflammatory drug control of the platform (Figures 4D,E).
Interestingly, the dietary phenolic acid GA reveals an anti-
inflammatory action at 100 µM comparing to HCD-fed animals
(Figures 4D,E). Notably, FA shows a comparably more potent
anti-inflammatory activity, strongly reducing NII at 25 µM
(Figures 4D,E).
Applications: Dose Response Analyses
and IBD Therapeutics
Successive dose-response analyses with GA and FA allow
validating these results as well as identifying the lowest
concentration at which these compounds are active and their
IC50 (Figures 5A,B). Both compounds reveal an increased anti-
inflammatory action with increasing molecular concentrations
(Figures 5A,B). GA is only anti-inflammatory at 100 µM based
on NII values (Figure 5A), having a IC50 of 44.13 µM. We
also confirm that FA is a highly potent active molecule. It
evokes an anti-inflammatory response in the HCD-GI model
at concentrations as low as 10 µM (Figure 5B), having a
half maximal inhibitory concentration (IC50) of 8.10 µM.
Importantly, FA shows some toxicity at 100 µM, with certain
larval suffering or death.
To illustrate the effectiveness of the HCD-GI platform in
identifying immunomodulatory molecules with relevance for
IBD, we evaluate the effect of common IBD therapeutics
(prednisolone and mesalamine or 5-ASA) on the NII phenotype
(Oehlers et al., 2011). The prescribed IBD drugs were
employed in the platform at concentrations equal or lower
to the ones reported in larval zebrafish enterocolitis models
(mesalamine = 0.33 mM; prednisolone 25 µM) (Oehlers et al.,
2011). Treatment with mesalamine reveals a strong anti-
inflammatory action when compared to HCD-fed animals.
NII levels in mesalamine-treated larvae are even below the
diet control SPE (Figure 6). In basal conditions, commensal
microbiota stimulates neutrophil migration and infiltration in
zebrafish larval intestines (Kanther et al., 2014). It is possible
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FIGURE 4 | The HCD-GI discovery platform reveals an anti-inflammatory action of gallic acid (GA) and ferulic acid (FA) on zebrafish intestinal neutrophilic
inflammation. (A) Schematic representation of the HCD-GI discovery platform in 6 dpf Tg(Lyz:NTR-mCherry)sh260. (B) Box plots of neutrophilic inflammation index
(NII) analysis at 15 h following SPE or HCD feeding for a 24 h period in larvae untreated or treated with DMSO at different concentrations. Central lines represent
median values, whereas box edges represent the 25 and 75th percentiles. Data were aggregated from 3 (DMSO: -) or 1 (DMSO: 0.01 or 1%) screening replicates
and pools of n biologically independent animal experiments disclosed in parenthesis. (C) Chemical structures of GA and FA. (D) Representative images of distal
intestine in GA, FA, or 1% DMSO-treated larvae. Caspase 1 Inhibitor I (Casp1) at 100 µM is used as positive anti-inflammatory control. White arrows correspond to
mCherry+ neutrophils in the intestines. Yellow arrows correspond to autofluorescence caused by pigments. The intestine is outlined in green. Scale bars, 100 µm.
(E) NII analysis in GA, FA, or DMSO-treated larvae. Data are presented as mean values ± SEM. Data were aggregated from 3 (SPE and HCD), 2 (Casp1), or 1 (GA
and FA) screening replicates and pools of n biologically independent animal experiments disclosed in parenthesis. Kruskal–Wallis test (one-way ANOVA on ranks)
was used for multiple comparisons. ****P < 0.0001; ***P < 0.001; *P < 0.05; ns, non-significant. Scheme (A) performed with images from Biorender.
that mesalamine exerts an anti-microbial effect impairing the
homeostatic recruitment of immune cells into the intestine
(Kaufman et al., 2009). On the other hand, administration
of prednisolone was successful at reducing the recruitment
of leukocytes to the intestine of HCD-fed larvae up to basal
NII levels. These results validate the fidelity of the IBD-like
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FIGURE 5 | Dose-response anti-inflammatory action of gallic acid (GA) and ferulic acid (FA) using the HCD-GI assay. (A) Neutrophilic inflammation index (NII) in
DMSO or GA-treated larvae. Data were aggregated from 3 (HCD), 2 (SPE, GA25, and GA100) or 1 (GA10 and GA50) experimental replicates and pools of n
biologically independent animal experiments disclosed in parenthesis. (B) NII in DMSO or FA-treated larvae. Data were aggregated from 6 (SPE and HCD), 3 (FA25
and FA100) or 2 (FA5 and FA10) experimental replicates and pools of n biologically independent animal experiments disclosed in parenthesis. Data are presented as
mean values ± SEM. Kruskal–Wallis test (one-way ANOVA on ranks) was used for multiple comparisons. ****P < 0.0001; *P < 0.05; ns, non-significant.
neutrophilic inflammation phenotype in our model and its
suitability for testing clinical grade molecules.
Further Applications and Advantages
Apart from monitoring immune cells infiltration, several
techniques can be applied to the HCD-GI assay to deeply
investigate the underlying mechanisms of a drug discovery
portfolio. A panel of anti- (e.g., IL-4 and IL-10) and pro-
inflammatory [e.g., IL-1β and IL-6, Tumour Necrosis Factor-α
(TNFα)] cytokines can be analyzed by quantitative polymerase
chain reaction (qPCR) in intestinal cells or by enzyme-linked
immunosorbent assay (ELISA) of the intestines’ supernatant.
Moreover, the levels of reactive oxygen species (ROS), TNFα,
IL-1β and Nuclear Factor kappa B (NF-κB)-signals, known to
FIGURE 6 | Treatment with conventional IBD therapeutics reduces the
neutrophilic inflammation index. Neutrophilic inflammation index (NII) analysis
in prednisolone (25 µM), mesalamine (5-ASA; 0.33 mM) or 1% DMSO-treated
larvae. Data were aggregated from 2 (HCD) or 1 (SPE, Prednisolone, and
5-ASA) experimental replicates and pools of n biologically independent animal
experiments disclosed in parenthesis. Data are presented as mean
values ± SEM. Kruskal–Wallis test (one-way ANOVA on ranks) was used for
multiple comparisons. ****P < 0.0001; **P < 0.01; ns, non-significant.
be upregulated in HCD-driven inflammation (Progatzky et al.,
2014), could be singly monitored by using specific transgenic
lines fed with HCD (Kanther et al., 2011; Enyedi et al., 2013;
Marjoram et al., 2015; Ogryzko et al., 2018). On the other hand,
leads can be validated in diet-based murine models of IBD
(Progatzky et al., 2014) or in more humanized 3D tissue systems
of the large intestine mimicking epithelial immune interactions
reflective of IBD (Roh et al., 2019). This would allow validating
the human relevance of leads.
Pitfalls and Troubleshooting
The HCD-GI assay is highly sensitive and selective and is
based on an unbiased quantification system (Figures 2B,C and
Supplementary Figure 1). Being the most error-inducing step
of the analysis performed manually, the operator can check
the data blindly and analyze the results for errors. One of the
confounding factors is the presence of red autofluorescence in
the pigmented cells that are localized close to the intestine.
If not excluded properly, those pigments introduce artifacts
in the NII value, overestimating it. On one side, we can opt
to employ phenylthiourea (PTU) during larval development, a
potent tyrosinase inhibitor commonly used to suppress pigment
formation in zebrafish. Yet, PTU can introduce another level
of complexity to the system, as this chemical can potentially
interfere with the compounds under test. We bypass this pitfall by
manually drawing the intestinal area and excluding the pigments
from the NII quantification (Figures 2B,C and Supplementary
Figure 1). Still, it is important to avoid the introduction of bias
from the operator in this step. Manual analysis should then be
performed by two independent and highly trained operators.
Another limitation of the method is that although the
quantification procedure is very sensitive it is manual. This can
be easily circumvented to allow a fully automated image analysis
suitable for high-throughput and high-content (HT/HC) screens.
In that case, we suggest using in the platform double transgenic
animals bearing fluorescently labeled gut epithelial cells and
neutrophils (Oehlers et al., 2011). This would allow the automatic
signal detection and quantification of neutrophil infiltration in
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larval intestines using the intestine-neutrophils colocalization
pixels as an inflammation index (Wittmann et al., 2012, 2015).
A possible error inducing step in the HCD-GI platform is to
manually place larvae in wells after the 25 or 100 µM solutions are
already prepared. This procedure may dilute the testing solutions
further. We minimize this error, using glass Pasteur pipettes with
a very small hole to transfer larvae. With these pipettes, larvae
often accumulate in groups at their tips and swim directly to
the medium without the need to add extra volume to the wells.
Like this, we can keep minimal the amount of medium that
is added during larvae transfer. Also, this problem is bypassed
by performing the screen at two different concentrations, which
allows a preliminary titration that can be further validated in
dose-response analyses. On the other hand, the same error would
occur if larvae were placed in wells before adding the compounds;
and in that case, the stock compound solution prepared in 100%
DMSO would enter in direct contact with larvae in the wells,
which can be very aggressive and should be avoided. For all these
reasons we suggest to first dilute and mix the compounds in the
medium before exposing the larvae to the testing concentrations.
Notably, with robotic liquid handling of larvae this error can be
circumvented (Wittmann et al., 2012, 2015).
Finally, as in previously reported screening approaches
(Wittmann et al., 2012, 2015; Oehlers et al., 2017), we opted for
a prolonged compound treatment to ensure the identification of
all the compounds with possible immunomodulatory action in
our setting. This option, however, does not allow to discriminate
at which level compounds are acting or if they have a preventive
or therapeutic potential. Still, after a first-pass screen, hits can be
further tested to address how they are protective against HCD-
induced intestinal inflammation. For instance, even if protection
would occur at the level of cholesterol uptake this beneficial effect
could be exploited as a preventive strategy in equivalent human
exposure scenarios.
DISCUSSION
Dietary cholesterol-induced intestinal inflammation in larval
zebrafish is a highly physiological model that recapitulates
hallmark aspects of human IBD. In acute settings, these include
the induction of pro-inflammatory pathways and degradative
enzymes and the infiltration of innate immune cells in the
intestines (Progatzky et al., 2014). After prolonged feeding
schemes it leads to functional dysregulation as well as systemic
pathologies (Progatzky et al., 2014). In Progatzky et al.,
significant differences in myeloid cell accumulation occurred
with groups of more than 30 larvae fed with HCD. These
numbers of larvae turn to be high and render screening strategies
quite laborious. Here we report an optimized version of this
model that is highly suitable for a drug-discovery platform
in a whole organism context. By manipulating the dietary
strategy to 24 h feeding, the HCD-GI assay reveals a robust
degree of neutrophilic infiltration with groups of circa 12
larvae that is highly consistent between experiments (Figure 2
and Figures 3C,D). Neutrophilic infiltration is measured with
a standardized protocol based on image deconvolution and
analysis of an intestinal inflammation index, NII (Figures 2B,C
and Supplementary Figure 1). Translating the HCD-GI assay
into a discovery platform – the HCD-GI discovery platform
(Figure 1) – allows the identification of immune-modulatory
compounds of acute neutrophilic inflammation with potential
relevance for IBD.
There is a clear unmet need to find new efficient treatments
for IBD. This protocol was devised to apply zebrafish as a
valuable in vivo model for compound discovery efforts, as the
effects of molecules acting on intestinal inflammation can be
straightforwardly studied in the context of an entirely functional
innate immune system. A powerful aspect of our set-up is the use
of transgenics highlighting the innate immune cell compartment,
namely neutrophils, that allows monitoring the pathophysiology
of an acute inflammatory response in vivo. Besides, a unique
advantage of our method is the fact that an intestinal-targeted
damage via dietary intake renders manual larvae manipulation
minimal, thus permitting the screening in medium or high-
throughput formats (Oehlers et al., 2011; Wittmann et al., 2012,
2015). Moreover, adverse and toxic effects of compounds and off-
target outcomes can be evaluated in our platform, as compounds’
toxicity usually leads to larval deformities or death. In that case,
it is possible to perform dose-response experiments over a range
of well tolerated concentrations. This turns to be more relevant
when the toxic compound belongs to a family of molecules that is
known to exert promising immune modulatory actions.
Two high-content small molecule screens on DSS- and TNBS-
induced enterocolitis have been reported in larval zebrafish
(Oehlers et al., 2017). These chemicals induce colitis either by
direct toxicity on epithelial cells or by disruption of intestinal
barrier integrity. One of the drawbacks of using these agents in
drug-screening assays are their extra-intestinal effects (Oehlers
et al., 2011). As DSS or TNBS are added directly to the water
medium, the route of exposure is not controlled and may lead to
potential interactions with any epithelial surface and consequent
skin damage (Oehlers et al., 2011). For instance, a relevant extra-
intestinal consequence of TNBS treatment in larval zebrafish is
the induction of leukocytosis (Oehlers et al., 2011). Although
leukocytosis is a recognized hallmark of IBD, it is not clear
how TNBS is inducing the redistribution of neutrophils from
CHT region to the periphery. Another disadvantage is that these
chemicals may react with the compounds under test (Oehlers
et al., 2017). This may lead to toxicity or may provoke the
tested compounds to lose their activity along the assay (Oehlers
et al., 2017). As said, using diet as an incitant of acute intestinal
inflammation avoids all the pitfalls underlying DSS or TNBS
immersion, as is a more controlled, targeted, selective, and
physiological trigger.
Similar to Oehlers et al. (2017) or other screens capable
of identifying immunomodulatory drugs (Wittmann et al.,
2012, 2015), we here present a screening strategy based
on a prolonged compound treatment. This strategy ensures
that all the compounds with immunomodulatory functions
on acute intestinal inflammation are identified and avoids
excluding putative candidates at early stages of a discovery
plan. After a first-pass screen, hits should be validated and
further investigated for their preventive or therapeutic action.
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By modifying duration and timing of compound application in
the HCD-GI discovery platform, it is possible to discriminate
whether molecules have a more preventive or treatment potential.
For example, the dietary phenolic acids like FA or GA have
a huge preventive and nutraceutical potential besides their
possible pharmacological applications; and, nowadays, the ability
to modulate diet to prevent daily an IBD condition is a highly
attractive and an ever-demanding proposition for increasing
quality of life.
Previous drug-repurposing screens in larval zebrafish
enterocolitis models employed only qualitative observational
identification of screening hits (Oehlers et al., 2017). We
improved this approach by developing a semi-automated image
acquisition and processing combined with quantitative image
analysis for accurate quantification of NII. The intestinal area
and red-labeled neutrophils are imaged 15 h post feeding,
when intestines are perfectly emptied and the inflammation
peak is most likely occurring (Progatzky et al., 2014). Red-
fluorescent images of neutrophils are deconvolved calculating
a theoretical Point-Spread-Function (PSF) and parameters are
carefully chosen to provide the best signal improvement without
artifacts. Manual drawing of the intestines permits calculating
the red-fluorescent area of neutrophils inside intestines, the
NII parameter, while correcting for pigments’ autofluorescence
that must be excluded from the analysis (Figures 2B,C and
Supplementary Figure 1). This parameter allows the analysis of
inflammation through the application of an intensity threshold
that reduces the operator bias and avoids the more laborious
calculation of infiltrated cell numbers. Similar analysis has been
performed for an automated high-content inflammation assay in
zebrafish (Wittmann et al., 2012, 2015).
An option to make the HCD-GI discovery platform valuable
for high-throughput and high-content (HT/HC) screens is to
perform the protocol in double transgenic larvae highlighting
both the intestinal enterocytes and the neutrophils (Oehlers et al.,
2011). This would allow automatic signal detection and fully
automated quantification of intestine-neutrophils colocalization
pixels as an index of intestinal inflammation (Wittmann et al.,
2012, 2015). Besides, this would automatically eliminate artifacts
introduced by red autofluorescent pigments, as these would not
colocalize with the intestinal labeling.
Intestinal neutrophilic infiltration is the readout system of the
HCD-GI assay and platform. While the role of neutrophils in
IBD has been investigated in animal models, their contribution
to disease pathogenesis remains controversial and no molecules
targeting neutrophils are validated for IBD treatment (Wéra et al.,
2016). Controversy arises from the dual roles of neutrophils in
inflammation. Neutrophils can be either beneficial for bacterial
clearance and resolution of inflammation or detrimental when
over-activated, leading to collateral tissue damage. It is therefore
proposed that both functional deficiency and hyper-reactivity of
neutrophils can induce intestinal inflammation in IBD (Wéra
et al., 2016). For example, in UC the degree of neutrophils
infiltration in the colon as well as their increased activity
have been linked to the severity of the disease (Raab et al.,
1993; Demir et al., 2015). Conversely, neutrophil dysfunction
has been observed in CD patients (Segal and Loewi, 1976;
Harbord et al., 2006). Above this duality, a powerful feature of
our platform is the possibility to categorize compounds as anti-
or pro-inflammatory when, respectively, reducing or increasing
the NII inflammation index (Figure 4). Compounds belonging to
each one of the categories can be further validated in independent
experiments, as they might exert their effect in a dose-dependent
manner (Figure 5). We could also expand the applicability of the
HCD-GI platform to identify compounds affecting the resolution
of neutrophilic inflammation. In that case, the timeframe at
which resolution occurs should be monitored, which is between
18 and 24 h post feeding for a 6 h feeding strategy (Progatzky
et al., 2014). Interestingly, the presented technique could also
offer the possibility to be utilized for the identification of
mutations in genes affecting neutrophil migratory behavior.
Finally, from a molecular point of view, identifying new
molecules acting on neutrophil infiltration capacity will improve
our understanding of their mode of action and ultimately provide
new therapeutic avenues that urge for IBD.
The zebrafish is an organism widely used in inflammation
biology. The anti-inflammatory activity of food compounds
has been already assayed in this model to evaluate their
protective immunomodulatory functions (Arteaga et al., 2018).
For the proof-of-concept of the platform, we here use two
dietary phenolic acids, namely gallic acid (GA) and ferulic acid
(FA), with well-described anti-inflammatory and antioxidant
properties in murine models of IBD (Sadar et al., 2007;
Pandurangan et al., 2015; Kandhare et al., 2016; Zhu et al., 2019;
Yang et al., 2020). Indeed, we verified that both compounds
reduced the inflammation index NII in animals after the
induction of inflammation with HCD (Figures 4D,E). They
exerted their effect in a dose-dependent manner, being FA more
potent (Figures 5A,B). We also validated our IBD-like model
using conventional anti-inflammatory IBD therapeutics, such as
mesalamine and prednisolone (Figure 6A). The fidelity of our
model was confirmed as both drug indications reduced the NII
to homeostatic levels or below (Figure 6A). Altogether, these
results suggest that the anti-inflammatory capacity of compounds
can be evaluated with the HCD-GI discovery platform, and that
the protocol creates a physiologically relevant environment for
screening of clinical grade immune modulators for IBD.
In conclusion, the optimized HCD-GI assay serves as a simple,
physiological, innovative, cost- and time-saving strategy to ease
and accelerate drug discovery, or drug repurposing efforts, by
providing potential new lead molecules relevant for IBD. This will
serve as a jumping-off point for more profound analyses of drug
mechanisms and pathways involved in the disease innate immune
responses. Finally, using this assay at early phases of a drug
discovery pipeline may provide readily available information
on drug tolerance, toxicity, dosage as well as potential off-
target effects that will reduce action risks and costs during
drug development.
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